Savara Inc. (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analysts hold a “Moderate Buy” consensus on Savara, with six buy ratings, one strong-buy rating, and one sell rating among eight covering brokerages. The average 12-month price target is $10.00, compared with the stock’s recent price of $5.42.
• Institutional investors and hedge funds own approximately 87.93% of Savara’s outstanding shares, while several investment firms recently initiated positions.
• Savara reported a quarterly loss of $0.16 per share, missing the consensus estimate of a $0.14 loss. The clinical-stage biotechnology company is developing inhaled molgramostim to treat autoimmune pulmonary alveolar proteinosis.

Savara Inc. (NASDAQ:SVRA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $10.00.

Several analysts recently commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Savara in a research note on Friday, July 17th. Wall Street Zen lowered shares of Savara from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th.

Institutional Investors Weigh In On Savara

A number of institutional investors and hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. acquired a new stake in Savara in the 1st quarter valued at about $57,000. Sequoia Financial Advisors LLC acquired a new position in Savara during the second quarter worth about $69,000. E Fund Management Co. Ltd. purchased a new stake in shares of Savara in the second quarter valued at about $77,000. Inceptionr LLC purchased a new stake in shares of Savara in the first quarter valued at about $84,000. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Savara in the second quarter valued at approximately $87,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Savara Trading Up 5.7%

Shares of SVRA stock opened at $5.42 on Friday. The business's fifty day moving average price is $5.50 and its 200 day moving average price is $5.45. The firm has a market capitalization of $1.11 billion, a PE ratio of -9.34 and a beta of 0.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. Savara has a 1-year low of $3.34 and a 1-year high of $7.01.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). As a group, sell-side analysts forecast that Savara will post -0.61 EPS for the current fiscal year.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's primary focus is autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which abnormal accumulation of surfactant in the lungs can impair breathing and oxygen exchange.

Savara's lead product candidate is molgramostim, an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is designed to help restore the function of pulmonary alveolar macrophages, the immune cells responsible for clearing excess surfactant from the lungs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.